Literature DB >> 8943276

Crystal structure of an antagonist mutant of human growth hormone, G120R, in complex with its receptor at 2.9 A resolution.

M Sundström1, T Lundqvist, J Rödin, L B Giebel, D Milligan, G Norstedt.   

Abstract

Human growth hormone binds two receptor molecules and thereby induces signal transduction through receptor dimerization. At high concentrations, growth hormone acts as an antagonist because of a large difference in affinities at the respective binding sites. This antagonist action can be enhanced further by reducing binding in the low affinity binding site. A growth hormone antagonist mutant Gly-120 --> Arg, has been crystallized with its receptor as a 1:1 complex and the crystal structure determined at 2.9 A resolution. The 1:1 complex is remarkably similar to the native growth hormone-receptor 1:2 complex. A comparison between the two structures reveals only minimal differences in the conformations of the hormone or its receptor in the two complexes, including the angle between the two immunoglobulin-like domains of the receptor. Further, two symmetry-related 1:1 complexes in the crystal form a 2:2 complex with a large solvent inaccessible area between two receptor molecules. In addition, we present here a native human growth hormone-human growth hormone-binding protein 1:2 complex structure at 2.5 A resolution. One important difference between our structure and the previously published crystal structure at 2.8 A is revealed. Trp-104 in the receptor, a key residue in the hormone-receptor interaction, has an altered conformation in the low affinity site enabling a favorable hydrogen bond to be formed with Asp-116 of the hormone.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8943276     DOI: 10.1074/jbc.271.50.32197

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  23 in total

1.  Computational alanine scanning with linear scaling semiempirical quantum mechanical methods.

Authors:  David J Diller; Christine Humblet; Xiaohua Zhang; Lance M Westerhoff
Journal:  Proteins       Date:  2010-08-01

2.  Allosteric Dynamic Control of Binding.

Authors:  Fidan Sumbul; Saliha Ece Acuner-Ozbabacan; Turkan Haliloglu
Journal:  Biophys J       Date:  2015-08-31       Impact factor: 4.033

3.  LIF receptor-gp130 interaction investigated by homology modeling: implications for LIF binding.

Authors:  D K Smith; H R Treutlein
Journal:  Protein Sci       Date:  1998-04       Impact factor: 6.725

4.  Isolated growth hormone deficiency in a Chihuahua with a GH1 mutation.

Authors:  Aki Iio; Shingo Maeda; Tomohiro Yonezawa; Yasuyuki Momoi; Tomoki Motegi
Journal:  J Vet Diagn Invest       Date:  2020-07-09       Impact factor: 1.279

Review 5.  Interleukin-6: structure-function relationships.

Authors:  R J Simpson; A Hammacher; D K Smith; J M Matthews; L D Ward
Journal:  Protein Sci       Date:  1997-05       Impact factor: 6.725

Review 6.  Thermodynamics-based drug design: strategies for inhibiting protein-protein interactions.

Authors:  Arne Schön; Sonia Y Lam; Ernesto Freire
Journal:  Future Med Chem       Date:  2011-07       Impact factor: 3.808

7.  Optimization of CD4/gp120 inhibitors by thermodynamic-guided alanine-scanning mutagenesis.

Authors:  Yingyun Liu; Arne Schön; Ernesto Freire
Journal:  Chem Biol Drug Des       Date:  2013-01       Impact factor: 2.817

8.  Site2 binding energetics of the regulatory step of growth hormone-induced receptor homodimerization.

Authors:  Scott T R Walsh; Liz M Jevitts; Juliesta E Sylvester; Anthony A Kossiakoff
Journal:  Protein Sci       Date:  2003-09       Impact factor: 6.725

9.  Activation of growth hormone receptors by growth hormone and growth hormone antagonist dimers: insights into receptor triggering.

Authors:  Ning Yang; John F Langenheim; Xiangdong Wang; Jing Jiang; Wen Y Chen; Stuart J Frank
Journal:  Mol Endocrinol       Date:  2007-12-20

10.  Small chicken growth hormone (scGH) variant in the neural retina.

Authors:  Marie-Laure Baudet; Steve Harvey
Journal:  J Mol Neurosci       Date:  2007       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.